Lazarus, Jeffrey V.
Ortiz, Alberto
Tyrovolas, Stefanos
Fernández, Esteve
Guy, Danielle
White, Trenton M.
Ma, Rui
Hay, Simon I.
Naghavi, Mohsen
Soriano, Joan B.
García-Basteiro, Alberto L.
Ayuso-Mateos, Jose L.
Bassat, Quique
Benavides, Fernando G.
Giné-Vázquez, Iago
Haro, Josep Maria
Koyanagi, Ai
Martinez-Raga, Jose
Padron-Monedero, Alicia
Peñalvo, José L.
Pérez-Gómez, Jorge
Rojas-Rueda, David
Sarmiento-Suárez, Rodrigo
Tabarés-Seisdedos, Rafael
,
Article History
Received: 3 June 2022
Accepted: 18 November 2022
First Online: 7 December 2022
Competing interests
: J.V.L. reports grants from AbbVie, Gilead Sciences, MSD, and Roche Diagnostics; consulting fees from NovoVax; payment or honoraria for lectures, presentations, speakers’ bureaus, and educational events from AbbVie, Gilead, Sciences, Intercept, and Janssen; participation on a Data Safety Monitoring Board with the QuickStart Study; and leadership, unpaid, with the EASL international Liver Foundation and HIV Outcomes; all outside the submitted work. A.O. reports (all outside the submitted work) grants from Sanofi and consultancy or speaker fees or travel support from Advicciene, Astellas, Astrazeneca, Amicus, Amgen, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Novo-Nordisk, and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes. All other authors declare no competing interests.